These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 33571454)

  • 1. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
    Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
    Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
    Adriaenssens AE; Biggs EK; Darwish T; Tadross J; Sukthankar T; Girish M; Polex-Wolf J; Lam BY; Zvetkova I; Pan W; Chiarugi D; Yeo GSH; Blouet C; Gribble FM; Reimann F
    Cell Metab; 2019 Nov; 30(5):987-996.e6. PubMed ID: 31447324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
    Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
    Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulating intestinal GIP release reduces food intake and body weight in mice.
    Lewis JE; Nuzzaci D; James-Okoro PP; Montaner M; O'Flaherty E; Darwish T; Hayashi M; Liberles SD; Hornigold D; Naylor J; Baker D; Gribble FM; Reimann F
    Mol Metab; 2024 Jun; 84():101945. PubMed ID: 38653401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.
    Killion EA; Chen M; Falsey JR; Sivits G; Hager T; Atangan L; Helmering J; Lee J; Li H; Wu B; Cheng Y; Véniant MM; Lloyd DJ
    Nat Commun; 2020 Oct; 11(1):4981. PubMed ID: 33020469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism.
    Boer GA; Keenan SN; Miotto PM; Holst JJ; Watt MJ
    Am J Physiol Endocrinol Metab; 2021 Apr; 320(4):E835-E845. PubMed ID: 33645252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
    PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system.
    Adriaenssens AE; Gribble FM; Reimann F
    Peptides; 2020 Mar; 125():170194. PubMed ID: 31697967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of energy metabolism through central GIPR signaling.
    Liskiewicz A; Müller TD
    Peptides; 2024 Jun; 176():171198. PubMed ID: 38527521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
    Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
    Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice.
    Isken F; Pfeiffer AF; Nogueiras R; Osterhoff MA; Ristow M; Thorens B; Tschöp MH; Weickert MO
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E350-5. PubMed ID: 18505834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
    Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
    Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
    Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
    J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
    Maida A; Lamont BJ; Cao X; Drucker DJ
    Diabetologia; 2011 Feb; 54(2):339-49. PubMed ID: 20972533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
    Lu SC; Chen M; Atangan L; Killion EA; Komorowski R; Cheng Y; Netirojjanakul C; Falsey JR; Stolina M; Dwyer D; Hale C; Stanislaus S; Hager T; Thomas VA; Harrold JM; Lloyd DJ; Véniant MM
    Cell Rep Med; 2021 May; 2(5):100263. PubMed ID: 34095876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A; Aihara E; Christe ME; Varga G; Beyer TP; Ruan X; Beebe E; O'Farrell LS; Bellinger MA; Austin AK; Lin Y; Hu H; Konkol DL; Wojnicki S; Holland AK; Friedrich JL; Brown RA; Estelle AS; Badger HS; Gaidosh GS; Kooijman S; Rensen PCN; Coskun T; Thomas MK; Roell W
    Cell Metab; 2024 Jul; 36(7):1534-1549.e7. PubMed ID: 38878772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.